Lucid Scientific, Inc.

Lucid Scientific, Inc. is a US-based company dedicated to developing innovative monitoring systems that provide real-time insights into cellular metabolism and oxygen utilization for healthcare and research sectors. Lucid Scientific, Inc. specializes in cellular oxygen consumption monitoring technology.

Founded by Richard Bryan and Walker Inman, the company is headquartered in Atlanta, US. The company recently raised USD 8. 80 mn in Series A funding on August 25, 2023, led by IAG Capital Partners, with participation from Dynamk Capital and GRA Venture Fund. This funding round marks the total amount raised to USD 8.

80 mn, with a current company valuation of USD 24. 79 mn. Lucid Scientific, Inc. offers a specialized Cellular Oxygen Consumption Rate Monitoring System that delivers real-time insights into cellular metabolism and oxygen utilization.

This technology serves healthcare providers, research institutions, and biotechnology companies, focusing on patient outcomes and enhancing research capabilities concerning cellular health. The system aids in diagnosing conditions and assessing treatment efficacy, catering to clinicians optimizing patient care and researchers in cellular biology and metabolic disorders. Their products are marketed in North America, Europe, and select Asian markets, ensuring efficient and accurate monitoring of cellular functions. The revenue model of Lucid Scientific, Inc.

revolves around direct sales of the Cellular Oxygen Consumption Rate Monitoring System, often accompanied by service agreements for software updates and technical support. The company also seeks partnerships with research organizations, enabling access to their technology for advanced studies. Pricing structures vary based on product configurations and service agreements, emphasizing a direct-to-consumer approach that supports their solutions in cellular monitoring. In August 2023, Lucid Scientific, Inc.

raised USD 8. 88 mn in Series A funding to support growth in product offerings and expand its workforce across production, sales, and marketing departments. The company plans to enhance its existing product line and target expansion into new markets, including regions within North America and Europe, by 2024. This strategic funding will facilitate the development and launch of upcoming products designed to improve cellular monitoring capabilities.